THIS WEEK IN NEPHROLOGY: Dr. Parikh and I discuss the definition and implementation of the Four Pillars of Care in patients with renal insufficiency. February 26, 2025
Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss best practices for titration of GLP-1 medications for optimal weight loss. February 17, 2025 Disclosures: TBD
Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss new oral semaglutide and the SOUL trial which lowered death, MI and stroke rates by 14% in patients with diabetes. December 18, 2024 Disclosures: TBD
Dr. McGuire, Dr. Jastreboff and Dr. C Michael Gibson discuss the SURMOUNT 1 Trial of Tirzepatide and how we may be able to diminish the progression from pre-diabetes to diabetes. December 9, 2024 Disclosures: TBD
von Willebrand factor molecules cross link and form a net around a blood clot holding it together. Drs. Shahid Nimjee and Gibson discuss a new vWf inhibitor that breaks apart this net & opening closed arteries but leaving a patch of fibrin strands across the site of plaque rupture which would have been dissolved by fibrinolytics potentially causing bleeding. December 4, 2024 Disclosures: TBD
Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia (BROOKLYN) November 18, 2024 Disclosures: TBD
Dr. Katherine R Tuttle and Dr. C. Michael Gibson Discuss: Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial November 18, 2024 Disclosures: TBD
Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles (KRAKEN) November 18, 2024 Disclosures: TBD
Dr. Steven E Nissen and Dr. C. Michael Gibson Discuss: ALPACAR Phase 2 Trial of Zerlasiran: Multiple Doses of a Short-Interfering RNA Targeting Lipoprotein(a) Over 60 weeks. November 18, 2024 Disclosures: TBD
Dr. Rajeev K Pathak and Dr. C. Michael Gibson Discuss: Aggressive Risk Factor Reduction Study for Atrial Fibrillation (ARREST-AF) Implications for Ablation Outcomes: A Randomized Clinical Trial November 18, 2024 Disclosures: TBD
